End-stage renal disease
Conditions
Interventions
Group with major adverse cardiovascular events:None
No major adverse cardiovascular events occurred:None
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1 Age >= 18 years old; 2 The duration of hemodialysis treatment is >= 3 months and the number of dialysis times per week is >= 2 times
Exclusion criteria
Exclusion criteria: 1 Combined with peritoneal dialysis; 2 Have serious complications or stress diseases such as acute infection, malignant tumor, severe liver insufficiency, serious bleeding risk, etc.; 3 Patients with acute cardiovascular and cerebrovascular adverse events before initial hemodialysis; 4 Clinical data, blood biochemical indicators, blood pressure readings and other data missing > 20% patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whether major adverse cardiovascular events occurred; | — |
Secondary
| Measure | Time frame |
|---|---|
| Age;Gender;Drinking history;smoking history;Body Mass Index;Sleep condition;History of previous cardiovascular and cerebrovascular events;Hypertension;Coronary heart disease;Diabetes;Atrial fibrillation;Chronic history;Malnutrition;Left ventricular hypertrophy;Anaemia;Protopathy;Dialysis age;Weight growth rate;Age to start dialysis;Pre-dialysis systolic blood pressure;Diastolic pressure before dialysis;Mean arterial pressure;Arterial stiffness;Blood pressure variability;White blood cell count;Platelet count;Blood lipid;Blood Sugar;Serum lactic acid;Hemoglobin;Serum albumin;Serum calcium;Serum sodium;Serum phosphate;C-reactive protein;Serum uric acid;Urea clearance;Triglyceride;Total cholesterol;High density lipoprotein;Low-density lipoprotein;Very low density lipoprotein;Amino terminal brain natriuretic peptide precursor;Red blood cell distribution width - coefficient of variation;Red blood cell distribution width - standard deviation;Parathyroid hormone;Homocysteine;Whether to take warfarin;Whether to take clopidogrel;Whether to take aspirin;Whether to take antiplatelet drugs; | — |
Countries
China
Contacts
Public ContactJinping Ying
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed